NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Evogene Ltd. (EVGN) Stock Analysis

Evogene Ltd. (EVGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

EVGN

$0.54

−$0.01 (−1.82%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EVGN with… →

EVGN Key Statistics

As of Sep 4, 2026
Trading
Open
$0.54
Previous Close
$0.55
Day's Range
0.52–0.55
52-Week Range
0.37–1.50
Volume
62.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$8.50M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.13
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.71
Financials (FY)
Revenue (FY)
$3.85M−30.91%
Net Income (FY)
−$8.49M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.80M
1-Year Return
−55.00%
Dividend and dates
Earnings Date
November 19, 2026
Avg Volume
1.46M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EVGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−50.91%
2025−41.18%
2024−77.74%
2023+20.00%
2022−57.32%
2021−65.11%
2020+209.21%
2019−23.23%
2018−35.50%
2017−39.80%
2016 (partial year)−24.89%

As of September 4, 2026.

EVGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.85M−$8.49M−220.2%
2024$5.58M−$16.49M−295.6%
2023$2.98M−$23.88M−800.8%
2022$1.68M−$26.64M−1590.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.85M−$241.00K−$14.03M−$8.49M−220.2%
2024$5.58M$3.20M−$18.76M−$16.49M−295.6%
2023$2.98M$1.49M−$22.21M−$23.88M−800.8%
2022$1.68M$766.00K−$26.94M−$26.64M−1590.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EVGN Valuation vs Biotechnology Median

Median of 656 stocks
MetricEVGNBiotechnology medianvs median
P/S ratio5.1315.2666% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Evogene Ltd. (EVGN) is capitalised at $8.50M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 38 employees.

The 52-week range on file runs from $0.37 to $1.50. The most recent close on file for EVGN is $0.54, dated September 4, 2026. That is −$0.01 (−1.82%) against the previous close. The latest close sits 45.95% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.85M. Against the prior fiscal year total of $5.58M, that is a change of −30.91%. The same year closed with a net loss of $8.49M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.71.

Across the 4 fiscal years on file, revenue moves from $1.68M in 2022 to $3.85M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 5.13 times revenue. On price-to-sales that is 66.39% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −55.00%. Measured over 10 years, that is −38.11% a year compounded. Beta against the wider market is reported at 0.7. Daily returns over the trailing 10 years annualize to a volatility of 82.66%.

Growth & Income

The record shows no dividend for EVGN.

So far in 2026 the price is −50.91%. The strongest complete calendar year on file is 2020 at +209.21%; the weakest is 2024 at −77.74%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Evogene Ltd. (EVGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Evogene Ltd. EVGN $8.50M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Evogene Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Evogene Ltd.

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Visit website →